ESR1 and breast cancer: Overall, this data suggests that NEDD9 is elevated at the protein and RNA levels in HER2+ breast cancers, and that increased levels of NEDD9 correlate with lower RFS in the HER2+ subset of BC patients, but not in ER+ BCs.